Dublin, March 14, 2017 -- Research and Markets has announced the addition of the "Compliance Risk Management in Medical Devices, Pharmaceuticals, and Combination Products" conference to their offering.
Effective risk management is the hallmark of a successful corporation. Increasingly, it is also the hallmark of a compliant corporation. While Medical Devices, Pharmaceuticals, and Combination Products have had unique histories for the evolution of risk management, the management of compliance risk is a common business process for all three areas.
Enterprise Risk Management (ERM) is the generic term for managing the risks of an organization. ISO 31000 is the ERM ISO Standard. This standard provides guidance for organizations on implementing ERM solutions. ISO 9001 is the Quality Systeme Standard. ISO 9001 now requires to establish risk-based thinking. As a result, ISO 13485, the International Quality System Standard for Medical Devices, has been revised to include requirements for firms to implement Compliance Risk Management. These requirements are in addition to the requirements as currently defined by ISO 14971, the International Standard for Risk Management of Medical Devices.
What is the difference between Compliance Risk Management and Product Risk Management? What about acceptability criteria for Compliance Risk Management? Should we merge the Compliance Risk Management activities into the existing Risk Management for Products? What are the expectations for managing risk in Pharmaceuticals (cGMP)? How does the evolving landscape of Compliance Risk Management interface with the evolving landscape of Combination Products?
In this one and a half day workshop, you will learn how to implement effective Compliance Risk Management in your organization. It is important that key personnel understand what a successful implementation of both ERM and Product Risk Management (ISO 14971) looks like. There are existing tools that may be adapted to implement the new requirements efficiently.
Learning Objectives:
- Read and understand what the expectations are for manufacturers of Medical Devices, Pharmaceuticals, and Combination Products that will be regulated by ISO 13485.
- Understand how to utilize a risk-based approach to addressing Compliance Risk Management requirements.
- Evaluate the effectiveness of Risk Management for Compliance and Product (ISO 14971)
- Develop appropriate Acceptability Criteria for Product and Compliance Risk Management
- Discriminate between the expectations of Medical Devices, Pharmaceuticals, and Combination Products
- Implement new or revised tools for improving Risk Management outcomes, both audit and field performance
Who will Benefit:
- Senior quality managers
- Quality professionals
- Regulatory professionals
- Compliance professionals
- Production managers
- Manufacturing engineers
- Production engineers
- Design engineers and managers
- Process owners
- Quality engineers
- Quality auditors
- Document control specialists
For more information about this conference visit http://www.researchandmarkets.com/research/nv6vgj/compliance_risk
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Medical Devices


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Anta Sports Expands Global Footprint With Strategic Puma Stake
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs 



